Invenra has expanded its discovery and licensing collaboration with Exelixis to include an additional 20 oncology targets, the company announced today.

According to a release, the collaboration builds on the two companies’ ongoing relationship and license agreement to discover and develop mono-specific and multi-specific antibodies for incorporation into novel biologics to treat cancer.

“We believe the continued success of our collaboration with the Exelixis team speaks to the quality of our unique and versatile antibody discovery platform, and we are proud to continue to support the Exelixis oncology pipeline,” Invenra CEO Roland Green said in a statement.

Exelixis will pay Invenra an upfront fee of $15 million, as well as additional fees and funding for the option to nominate up to 20 additional targets in oncology.